Zuoli Pharma: Lingyi Bio's Parkinson’s Pipeline LY-N001 Continues Steady Progress in R&D

Gelonghui September 7th |Zhejiang Jolly Pharmaceutical Co., Ltd.Lingyi Biotech stated during an institutional research interview that the development of its Parkinson's pipeline, LY-N001, is proceeding as planned and major preclinical studies have been completed. This pipeline targets patients with a subtype of Parkinson’s disease associated with GBA1 gene mutations. The future goal is to file for IND approval in both China and the U.S., initiate clinical trials, and establish a global market presence. Lingyi Biotech is a company focused on the development of innovative drugs for monogenic hereditary diseases, specializing in creating gene therapies with differentiated advantages. In April 2025, the company increased its investment in Lingyi Biotech by 20 million yuan.